Ken Griffin Pds Biotechnology Corp Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Pds Biotechnology Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 900 shares of PDSB stock, worth $1,395. This represents 0.0% of its overall portfolio holdings.
Number of Shares
900
Previous 4,800
81.25%
Holding current value
$1,395
Previous $14,000
78.57%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding PDSB
# of Institutions
65Shares Held
4.06MCall Options Held
253KPut Options Held
70.4K-
Vanguard Group Inc Valley Forge, PA1.52MShares$2.36 Million0.0% of portfolio
-
Black Rock Inc. New York, NY487KShares$754,7980.0% of portfolio
-
Geode Capital Management, LLC Boston, MA415KShares$643,4250.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny234KShares$363,0230.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA134KShares$208,1030.0% of portfolio
About PDS Biotechnology Corp
- Ticker PDSB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,458,700
- Market Cap $44.1M
- Description
- PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies...